Deals & Corporate Governance

  • January 23, 2024

    Weil Helps Sanofi Buy Rare Diseases Co. For Up To $2.2B

    French healthcare giant Sanofi SA said Tuesday that it will buy a U.S. company that creates therapies for so-called orphan diseases for approximately $2.2 billion in cash as it seeks to expand its rare diseases products.

  • January 22, 2024

    Claims Review Nurses Say Work Should've Garnered OT

    Nurses who review appeals of denied medical procedure authorizations for healthcare providers are misclassified as overtime-exempt, a nurse told an Ohio federal court Monday in a proposed collective action.

  • January 22, 2024

    Mallinckrodt Trust Can Pursue Covidien Clawback Claims

    A litigation trust formed when Mallinckrodt PLC left Chapter 11 bankruptcy can continue pursuing some clawback claims against Covidien Unlimited Co. alleging Covidien committed actual fraud when it spun Mallinckrodt off in 2013, a Delaware bankruptcy judge ruled.

  • January 22, 2024

    FTC Fights Bids To Toss Texas Anesthesia Roll-Up Case

    The Federal Trade Commission urged a Texas federal court not to toss the agency's antitrust case against Welsh Carson Anderson & Stowe and U.S. Anesthesia Partners, saying the private equity firm orchestrated a "roll up" strategy to create a dominant anesthesiology practice.

  • January 22, 2024

    Cancer-Focused Arrivent Biopharma Eyes $150M IPO

    Lung cancer-focused Arrivent Biopharma Inc. set a price range for its planned initial public offering Monday, saying it plans to offer 8.3 million shares at a price range of $17 to $19, meaning it could raise an estimated $150 million through its IPO.

  • January 22, 2024

    Skin Care Drug Co. Timber Gets OK For Ch. 11 Sale To Lender

    A Delaware bankruptcy judge on Monday approved dermatology drug developer Timber Pharmaceuticals' plan for a Chapter 11 sale of its assets, with the debtor telling the court it intended to close the deal with a post-petition lender by the end of the day.

  • January 22, 2024

    Sandoz To Acquire Retinal Disease Biosimilar For $170M

    Sandoz Group AG said on Monday that it will buy a therapy for retinal diseases from U.S. biopharmaceutical company Coherus BioSciences Inc. for $170 million in cash, as the Swiss-German generic drugs business seeks to strengthen its ophthalmology portfolio.

  • January 19, 2024

    Law360 Names Firms Of The Year

    Eight law firms have earned spots as Law360's Firms of the Year, with 55 Practice Group of the Year awards among them, steering some of the largest deals of 2023 and securing high-profile litigation wins, including at the U.S. Supreme Court.

  • January 19, 2024

    Law360 Names Practice Groups Of The Year

    Law360 would like to congratulate the winners of its Practice Groups of the Year awards for 2023, which honor the attorney teams behind litigation wins and major deals that resonated throughout the legal industry this past year.

  • January 19, 2024

    UPMC Accused Of 'Draconian' Antitrust Plot To Trap Workers

    The University of Pittsburgh Medical Center was hit with a proposed class action Thursday accusing it of an "an overarching anti-competitive scheme" involving a "draconian system" to trap workers in jobs with suppressed pay and heightened workloads in a bid to maintain its dominance in the region.

  • January 19, 2024

    UpHealth's 'Full Pay' Ch. 11 Plan On Horizon, Committee Says

    Bankrupt medical tech company UpHealth is in talks with its official committee of unsecured creditors to submit a Chapter 11 plan by the end of April that would pay unsecured debts in full, the committee told a Delaware bankruptcy court in a statement supporting UpHealth's request to extend its exclusive plan filing window.

  • January 19, 2024

    JP Morgan, Others Must Face Sr. Care Investors' Claims

    Claims that a group of securities underwriters were negligent in a senior health care company's initial public offering have been kept alive by a Colorado federal judge.

  • January 18, 2024

    CG Oncology Aims To Raise Up To $212M As It Sets IPO Terms

    Bladder-cancer therapy company CG Oncology set terms for its planned initial public offering Thursday, saying it intends to offer 11.8 million shares for between $16 and $18 per share, meaning it could raise up to around $212 million if priced at the high point.

  • January 18, 2024

    BridgeBio Pharma Secures $1.25B For New Drug Launch

    Public biopharmaceutical company BridgeBio Pharma announced Thursday that it has raised up to $1.25 billion in capital from Blue Owl Capital and the Canada Pension Plan Investment Board to accelerate the launch of its new heart disease medicine acoramidis.

  • January 17, 2024

    Caremark Wants Tribe's Prescription Claim Suit Arbitrated

    Caremark LLC has asked an Arizon federal court to compel arbitration of a lawsuit the Muscogee (Creek) Nation and its health department filed claiming the pharmacy benefit manager failed to pay claims for prescription drugs.

  • January 17, 2024

    Boston's Ratio Therapeutics Raises $50M Series B For R&D

    Pharmaceutical startup Ratio Therapeutics has raised a fresh round of funding, the company announced Wednesday, closing on a $50 million Series B round that will be used to expand its research and development platforms and advance a treatment to clinical trials.

  • January 17, 2024

    VC Firm Gen­er­al Cat­a­lyst To Buy Nonprofit Sum­ma Health

    General Catalyst is acquiring Ohio-based health system Summa Health, the venture capital firm announced Wednesday, in a move that will convert the nonprofit hospital system into a for-profit entity.

  • January 17, 2024

    Health Co. Says Ex-CEO Sought 'Loyalty Oaths,' Revenge

    Summit Orthopedic Home Care has filed a federal suit in Ohio accusing its ex-CEO and his "cronies" of using oppressive behavior to gain control over operations and then using internal knowledge of Summit's relationships to benefit his new home healthcare business.

  • January 17, 2024

    Brown Rudnick Launches Life Sciences Consulting Division

    A pair of biotech veterans joined Brown Rudnick LLP in October to build a new consulting office called BR BioAdvisory Services, the firm announced Wednesday.

  • January 17, 2024

    PE-Backed Healthcare Provider BrightSpring Eyes $880M IPO

    Private equity-backed healthcare platform BrightSpring Health Services Inc. on Wednesday unveiled a price range for an estimated $880 million initial public offering, represented by Simpson Thacher & Bartlett LLP and underwriters counsel Latham & Watkins LLP.

  • January 16, 2024

    GC Named Head Of Nassau U Medical Center In Restructuring

    The board that oversees the 530-bed tertiary care teaching hospital Nassau University Medical Center has named its general counsel as interim president and CEO.

  • January 16, 2024

    Biotech Startup Alto Neuroscience Files To Go Public

    Psychiatric biotech company Alto Neuroscience is preparing to go public, according to a preliminary prospectus the company filed Friday.

  • January 16, 2024

    Therapy Co. Says Ex-Directors 'Raided' Staff And Patients

    Two psychotherapists who resigned from their roles as directors of a Pennsylvania-based mental health practice have been hit with a suit alleging they "brazenly solicited and raided" workers from the practice to launch their own therapy business.

  • January 16, 2024

    Union Funds Drop Suit Against CIA Janitorial Contractors

    Two union benefit funds have dropped their federal lawsuit against a pair of companies that staff janitorial workers and security guards at the Central Intelligence Agency's headquarters, agreeing in a stipulation of dismissal docketed Tuesday to stop pursuing claims that the companies withheld financial documents from fund-retained auditors.

  • January 16, 2024

    Crowell Adds Moses Singer Health Trio In New NYC Office

    Crowell & Moring LLP announced Tuesday that it has hired a team from Moses & Singer LLP with rare expertise in regulatory and compliance issues related to clinical trials for biotech and health tech companies.

Expert Analysis

  • Cannabis Considerations In Debt Collection, Credit Reporting

    Author Photo

    While companies that collect debts arising from cannabis purchases, and consumer reporting agencies that furnish information concerning such debts, may not be governed by consumer protection laws, they should probably act like it by implementing compliance programs that heed state and federal requirements, say Corey Scher and Joshua Horn at Fox Rothschild.

  • Don't Forget Alumni Engagement When Merging Law Firms

    Author Photo

    Neglecting law firm alumni programs after a merger can sever the deep connections attorneys have with their former firms, but by combining good data management and creating new opportunities to reconnect, firms can make every member in their expanded network of colleagues feel valued, say Clare Roath and Erin Warner at Troutman Pepper.

  • Interstate Cannabis Commerce May Be In Reach, With Caveats

    Author Photo

    California is the latest state to lay the groundwork for interstate cannabis commerce agreements, which may offer a solution to the overabundance of product in legal adult-use markets and survive constitutional challenges — but even then, obstacles to a national market will remain, say Adam Horowitz and Harry Berezin at Goodwin.

  • Without Stronger Due Diligence, Attys Risk AML Regulation

    Author Photo

    Amid increasing pressure to mitigate money laundering and terrorism financing risks in gatekeeper professions, the legal industry will need to clarify and strengthen existing client due diligence measures — or risk the federal regulation attorneys have long sought to avoid, says Jeremy Glicksman at the Nassau County District Attorney’s Office.

  • Abortion Pill Rulings Will Hinder FDA Authority

    Author Photo

    Although the Fifth Circuit recently stayed a Texas federal court's ruling that invalidated the U.S. Food and Drug Administration's approval of a commonly used abortion medication, several points made by the courts are worth considering for their potentially chilling effect on FDA authority and the challenges they may create for the life sciences industry, say attorneys at Morgan Lewis.

  • Cannabis Labor Peace Laws Lay Fertile Ground For Unions

    Author Photo

    State legislatures are increasingly passing cannabis laws that encourage or even mandate labor peace agreements as a condition for licensure, and though open questions remain about the constitutionality of such statutes, unionization efforts are unlikely to slow down, says Peter Murphy at Saul Ewing.

  • Every Lawyer Can Act To Prevent Peer Suicide

    Author Photo

    Members of the legal industry can help prevent suicide among their colleagues, and better protect their own mental health, by learning the predictors and symptoms of depression among attorneys and knowing when and how to get practical aid to peers in crisis, says Joan Bibelhausen at Minnesota Lawyers Concerned for Lawyers.

  • Building On Successful Judicial Assignment Reform In Texas

    Author Photo

    Prompt action by the Judicial Conference could curtail judge shopping and improve the efficiency and procedural fairness of the federal courts by implementing random districtwide assignment of cases, which has recently proven successful in Texas patent litigation, says Dabney Carr at Troutman Pepper.

  • Now Is The Time For Independent Industry Self-Regulation

    Author Photo

    The high level of trust in business, coupled with the current political and legal landscape, provides an opportunity for companies to play a meaningful role in finding solutions to public policy issues through the exploration of independent industry self-regulation models, says Eric Reicin at BBB National Programs.

  • AmEx Ruling Proves A Double-Edged Sword In Labor Antitrust

    Author Photo

    Though the U.S. Supreme Court's 2018 decision in Ohio v. American Express was a defense victory, both the plaintiff and defense bars have learned to use the case's holdings to their advantage, with particularly uncertain implications for labor antitrust cases, say Lauren Weinstein and Robert Chen at MoloLamken.

  • Do Videoconferences Establish Jurisdiction With Defendants?

    Author Photo

    What it means to have minimum contacts in a foreign jurisdiction is changing as people become more accustomed to meeting via video, and defendants’ participation in videoconferencing may be used as a sword or a shield in courts’ personal jurisdiction analysis, says Patrick Hickey at Moye White.

  • Takeaways From DOJ's Novel Insider Trading Indictment

    Author Photo

    The U.S. Department of Justice's recently announced insider trading charges in U.S. v. Peizer mark the first indictment based solely on an executive’s use of a Rule 10b5-1 trading plan, reflecting prosecutors' aggressive approach and providing insights for corporate executives, say attorneys at Cleary.

  • Humanism Should Replace Formalism In The Courts

    Author Photo

    The worrying tendency for judges to say "it's just the law talking, not me" in American decision writing has coincided with an historic decline in respect for the courts, but this trend can be reversed if courts develop understandable legal standards and justify them in human terms, says Connecticut Superior Court Judge Thomas Moukawsher.